Claims for Patent: 10,172,817

Summary for Patent: 10,172,817

Title:	Treatment and diagnosis of colon cancer
Abstract:	The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Inventor(s):	Tavazoie; Sohail (New York, NY), Loo; Jia M. (New York, NY)
Assignee:	The Rockefeller University (New York, NY)
Application Number:	15/630,024
Patent Claims:	1. A method for treating gastrointestinal cancer in a subject in need thereof, the method comprising administering to the subject beta-guanidinopropionic acid subsequent to at least one prior anti-cancer therapy to treat the gastrointestinal cancer, wherein the beta-guanidinopropionic acid is administered to the subject in an amount effective to suppress metastatic colonization of the gastrointestinal cancer. 2. The method of claim 1, wherein the prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy. 3. The method of claim 2, wherein the prior anti-cancer therapy is surgery. 4. The method of claim 2, wherein the prior anti-cancer therapy is radiation therapy. 5. The method of claim 1, the method further comprising administering to the subject one or more additional therapeutic agents. 6. The method of claim 5, wherein one or more additional therapeutic agents comprises cyclocreatine, a RNAi agent, a nucleic acid, a vector, 5-fluorouracil, Oxaliplatin, Irinotecan, Capecitabine, Gemcitabine, Cetuximab, Taxol, Avastin, folinic acid (leucovorin), Regorafenib, Zaltrap, topoisomerase I inhibitors, NKTR-102, Tivantinib, PX-866, Sorafenib, Linifanib, kinase inhibitors, Telatinib, XL281 (BMS-908662), Robatumumab, or IGF1-R Inhibitors. 7. The method of claim 6, where in the one or more additional therapeutic agent comprises 5-fluorouracil. 8. The method of claim 6, wherein the one or more additional therapeutic agent comprises Capecitabine. 9. The method of claim 6, wherein the one or more additional therapeutic agent comprises Gemcitabine. 10. The method of claim 6, wherein the one or more additional therapeutic agents comprises 5-fluorouracil, leucovorin, and oxaliplatin. 11. The method of claim 6, wherein the one or more additional therapeutic agents comprises capecitabine and oxaliplatin. 12. The method of claim 6, wherein the one or more additional therapeutic agents comprises 5-fluorouracil and leucovorin. 13. The method of claim 6, wherein the one or more additional therapeutic agents comprises 5-fluorouracil and oxaliplatin. 14. The method of claim 6, wherein the one or more additional therapeutic agents comprises irinotecan, 5-fluorouracil, and leucovorin. 15. The method of claim 1, wherein the gastrointestinal cancer is colorectal cancer. 16. The method of claim 1, wherein the gastrointestinal cancer is pancreatic cancer. 17. The method of claim 1, wherein the gastrointestinal cancer is gastric cancer. 18. The method of claim 1, wherein the gastrointestinal cancer is esophageal caner. 19. The method of claim 1, wherein the gastrointestinal cancer is metastatic gastrointestinal cancer. 20. The method of claim 1, wherein the method comprises the suppression of metastatic colonization of gastrointestinal cancer in the liver in a subject in need thereof. 21. The method of claim 1, wherein the gastrointestinal cancer has a decreased expression level of miRN-483-5p and/or miR551a and/or an increased expression level of CKB and/or SLC6a8.

Details for Patent 10,172,817

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-10-31
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-10-31
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-10-31